Innovating.works Conecta tu I+D

Showing 1 to 20 of 35 results

APOLLO2028: Improving mental health, wellbeing, and resilience of healthcare workers in Changing Environments CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un HORIZON EUROPE: HORIZON-HLTH-2023-CARE-04 The overall objective of the APOLLO2028 project is to provide health and care workers, organisations, and healthcare system funders and poli...
2023-12-01 - 2027-12-31 | Financiado

MuSiC4Diabetes: Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabe... CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 It will be a radically new approach for long-term continuous monitoring of insulin-treated persons with diabetes (ITD) moving from a glucose...
2023-06-21 - 2027-09-30 | Financiado

GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | Financiado

Bootstrap: Boosting Societal Adaptation and Mental Health in a Rapidly Digitalizing Post Pandemic Europe CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-01-two-stage BACKGROUND: Adolescents are at particularly high risk for digital technology overuse, including in response to the COVID pandemic, and are t...
2023-04-21 - 2028-06-30 | Financiado

PANCAID: PANcreatic CAncer Initial Detection via liquid biopsy CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will theref...
2022-12-02 - 2027-12-31 | Financiado

Chrom_rare: Unveiling the molecular basis of chromatinopathies to delineate innovative therapeutic solutions CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Chromatinopathies (CPs) are a group of rare genetic diseases, which share clinical features as well as causal genetic alterations, leading t...
2022-06-14 - 2026-12-31 | Financiado

FORGETDIABETES: A BIONIC INVISIBLE PANCREAS TO FORGET DIABETES CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-FETPROACT-2019-2020 FORGETDIABETES introduces a radically new approach to Type 1 Diabetes (T1D) treatment, by developing an immuno-optimized, fully-implantable,...
2020-05-28 - 2025-03-31 | Financiado

I-MOVE-COVID-19: Multidisciplinary European network for research prevention and control of the COVID 19 Pandemic CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020 I-MOVE-COVID-19 aims to obtain epidemiological, clinical and virological information about COVID-19 and patients infected with SARS-CoV-2, t...
2020-04-08 - 2022-06-15 | Financiado

MIRIADE: Multi omics Interdisciplinary Research Integration to Address DEmentia diagnosis CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-MSCA-ITN-2019 Dementia is currently diagnosed largely based on cognitive decline, while pathology starts years before symptom onset. To make progress in t...
2019-08-09 - 2024-08-31 | Financiado

MOBILISE-D: Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing...
2019-03-22 - 2024-06-30 | Financiado

SCAUT: Ser Col from finger to laboratory personalized and automated serum collection for laboratory diagn... CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-EIC-FTI-2018-2020 95% of blood collected via venipuncture is not used for diagnostic measurements, and needs to be disposed as biohazardous waste by incinerat...
2018-12-14 - 2022-03-31 | Financiado

Hypo-RESOLVE: Hypoglycaemia REdefining SOLutions for better liVEs CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diab...
2018-04-30 - 2023-10-31 | Financiado

ELBA: European Liquid Biopsies Academy Towards widespread clinical application of blood based diagnosti... CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-MSCA-ITN-2017 Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensiti...
2017-08-30 - 2022-09-30 | Financiado

RESPINE: REgenerative therapy of intervertebral disc a double blind phase 2b trial of intradiscal injection... CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER tramitó un H2020: H2020-SC1-2016-2017 The World Health Organisation (WHO) has included low back pain in its list of twelve priority diseases. Notably, Degenerative disc disease (...
2016-12-09 - 2023-06-30 | Financiado

COBIOPHAD: COMPACT BIOPHOTONIC PLATFORM FOR DRUG ALLERGY DIAGNOSIS CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-ICT-2015 Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens. Moreover, preventable adve...
2015-12-09 - 2019-07-31 | Financiado

EVOLPROOF: Are HPV vaccines evolution proof ? Multilevel evolutionary ecology of human oncoviruses CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: ERC-2014-CoG There is a threat that evolutionary responses can render vaccines ineffective, as illustrated by the emergence of the increasingly virulent...
2015-07-30 - 2022-02-28 | Financiado

I-MOVE-plus: I MOVE Integrated Monitoring of Vaccines Effects in Europe a platform to measure and compare effec... CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-PHC-2014-2015 The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the e...
2015-04-07 - 2018-10-31 | Financiado

ADIPOA2: Clinical trial of autologous adipose derived mesenchymal stromal cells ASC in the treatment of mil... CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un H2020: H2020-PHC-2014-2015 Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to preve...
2014-12-01 - 2019-12-31 | Financiado

BTCURE: BeTheCuRE CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER participó en un FP6: BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
2011-04-01 - 2017-03-31 | Financiado

CENTRE HOSPITALIER UNIVERSITAIRE MONTPEL...